San Francisco, Ca., USA - April 6, 2010, San Francisco, Ca., USA - OXiGENE, Inc., a clinical-stage biopharmaceutical company, announced the appointment of Tamar Howson and its current CEO, Dr. Peter J. Langecker, to its Board of Directors.
Article continues below
Ms. Howson's successful career spans 20 years in the pharmaceutical business, and her track record of nearly 100 transactions make her one of the industry's preeminent business development executives. Most recently, Ms Howson has been a member of the transaction team at JSB partners, a partnering consulting firm specializing in the biotechnology industry.
Previously, she served as Executive Vice President of Corporate Development for Lexicon Pharmaceuticals. Prior to Lexicon, she served as Senior Vice President of Corporate and Business Development and was a member of the executive committee at Bristol-Myers Squibb.
Earlier, Ms. Howson served as Senior Vice President and Director of Business Development at SmithKline Beecham. She also managed SR One Ltd., the $100 million venture capital fund of SmithKline Beecham. Ms. Howson has served as an independent business consultant and adviser to companies both in the United States and in Europe.
She held the position of Vice President, Venture Investments at Johnston Associates, a venture capital firm, and earlier as Director of Worldwide Business Development and Licensing for Squibb Corporation.
Ms. Howson currently serves on the boards of Idenix Pharmaceuticals, Inc. and S*Bio Pte Ltd. She also serves as a consultant to Pitango Venture Fund and is a member of the advisory board to Triana Venture Partners. She previously served on the boards of Ariad Pharmaceuticals, SkyePharma, NPS Pharma, Targacept, and HBA.
Ms. Howson received her M.B.A. in finance and international business from Columbia University. Educated as a chemical engineer, she holds a M.S. from the City College of New York and a B.S. from the Technion in Israel.
Peter J. Langecker, M.D., Ph.D., joined OXiGENE as Chief Development Officer in June 2009 and who was named interim CEO in October 2009 and permanent CEO in February 2010. ■